PARIS – Dechert LLP assisted HRA Pharma, as well as its shareholders Astorg Partners and Goldman Sachs, with its acquisition of the Compeed business from Johnson & Johnson.
HRA Pharma is a pharmaceutical company leader in emergency contraception which primary objective is to strengthen its position in the non-prescription drug market. With the acquisition of Compeed, a brand of plasters hold by Cilag Gmbh International, the German subsidiary of Johnson & Johnson, HRA Pharma is about to double in size.
The Paris-based Dechert team advising HRA Pharma included partners Alain Decombe and Isabelle Marguet assisted by associates Magali Stuber and Pierre-Henri Brieau (corporate); national partner Sophie Pelé assisted by associate Jessica Garestier (commercial and regulatory); national partner Marie Fillon assisted by associate Colin Devinant (intellectual property); partner Mélanie Thill-Tayara assisted by associates Marion Provost and Raimbaut Lacoeuilhe (antitrust/competition); associates Thibault Meiers and Victoria Hamel (labor and employment) and partner Ross Allardice in London (corporate).
Read the press release in French (PDF): “HRA Pharma’s Acquisition of Compeed”
About Dechert
Dechert is a global law firm focused on sectors with the greatest complexities and highest regulatory demands. We deliver practical commercial insight and judgment to our clients' most important matters. Nothing stands in the way of giving clients the best of the firm's entrepreneurial energy and seamless collaboration in a way that is distinctively Dechert.
Related Professionals
